The federal drug pricing program 340B helps hospitals and clinics in Virginia and across the nation care for underserved ...

CMS proposes paying 340B-acquired drugs at ASP minus 33.4% starting CY 2027, replacing ASP plus 6%, based on survey findings that acquisition costs are well below ASP. Projected 2027 impact includes ...

CMS Administrator Dr. Oz proposes deep cuts to the 340B drug program to lower Medicare costs. Learn how this affects ...

The Centers for Medicare and Medicaid Services’ annual outpatient hospital pay increase proposal has come with a potential ...

A clear look at the 340B program: how hospitals generate revenue from drug discounts, why it has expanded, and the growing policy debate.

CMS would set 340B drug payment at ASP–33.4%, lowering Medicare and beneficiary drug outlays while redistributing equivalent ...

A recent congressional hearing on 340B is the latest iteration of a standoff between two pillars of the healthcare industry—hospitals and pharmaceutical manufacturers—both of which have powerful ...

On July 31, 2025, the Health Resources and Services Administration (HRSA), Office of Pharmacy Affairs (OPA) issued a 340B Drug Pricing Program notice (the “Notice”) announcing the launch of a ...

A federal judge on Monday temporarily blocked the U.S. administration’s planned 340B Rebate Model Pilot Program, finding that regulators likely failed to meet basic administrative law requirements ...

The 340B Drug Pricing Program was created in 1992 to increase access to hospital outpatient medications for low‐income and uninsured patients by allowing covered entities that serve these patients to ...

Halo340B today called on Federally Qualified Health Centers and other 340B covered entities to take a more strategic and mission-driven approach to understanding their 340B gross-to-net performance.